<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708236</url>
  </required_header>
  <id_info>
    <org_study_id>ORTD1-COV-001</org_study_id>
    <nct_id>NCT04708236</nct_id>
  </id_info>
  <brief_title>A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia</brief_title>
  <official_title>A Blinded, Controlled, Escalating Dose Study of ORTD-1 for Treatment of Hospitalized Patients With SARS-CoV-2 (COVID-19) Related Pneumonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oryn Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oryn Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, blinded, vehicle-controlled dose-escalation study. Initial enrollment&#xD;
      and treatment will be conducted as an inpatient study. Patients will be randomized 2:1,&#xD;
      ORTD-1 treatment versus vehicle control. Patients will be allocated into 1 of 3 sequential&#xD;
      escalating dose cohorts. Blinded study drug will be infused intravenously once daily for 5&#xD;
      consecutive days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Patients will be allocated into 1 of 3 sequential escalating dose cohorts and randomized to ORTD-1 treatment versus vehicle control within each cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Number of participants with treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Number of participants with Grade 3 or higher laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Number of participants who develop antibodies to ORTD-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring intubation</measure>
    <time_frame>Day 1-65</time_frame>
    <description>The requirement of intubation and invasive ventilation will be assessed for patients at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days requiring supplemental oxygen</measure>
    <time_frame>Day 1-65</time_frame>
    <description>Percentage of days for which the patient requires supplemental oxygen will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Day 1-65</time_frame>
    <description>Overall survival is defined as the time from enrollment until death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peripheral blood oxygen levels (SpO2)</measure>
    <time_frame>Day 1-Day 7, Day 14, Day 21, Day 28, Day 35, Day 65</time_frame>
    <description>SpO2 over time will be measured by pulse oximetry.</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Level of the inflammatory biomarker IL-6 in blood will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Level of the inflammatory biomarker TNF- alpha in blood will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Level of the inflammatory biomarker C-reactive protein in blood will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum ferritin</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Level of serum ferritin in blood will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>D-dimer</measure>
    <time_frame>Through Day 65</time_frame>
    <description>Level of D-dimer in blood will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentration of ORTD-1 (Pharmacokinetics)</measure>
    <time_frame>Day 1-Day 6, Day 14, Day 21, Day 35, Day 65</time_frame>
    <description>Serum concentration of ORTD-1 will be measured following IV infusion and during follow-up</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>ORTD-1 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: ORTD-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORTD-1 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: ORTD-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORTD-1 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3 : ORTD-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 4: Vehicle control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORTD-1 low dose</intervention_name>
    <description>ORTD-1 will be administered intravenously once daily for 5 consecutive days.</description>
    <arm_group_label>ORTD-1 Low dose</arm_group_label>
    <other_name>Intervention 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORTD-1 mid dose</intervention_name>
    <description>ORTD-1 will be administered intravenously once daily for 5 consecutive days.</description>
    <arm_group_label>ORTD-1 Mid Dose</arm_group_label>
    <other_name>Intervention 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORTD-1 high dose</intervention_name>
    <description>ORTD-1 will be administered intravenously once daily for 5 consecutive days.</description>
    <arm_group_label>ORTD-1 High Dose</arm_group_label>
    <other_name>Intervention 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle control</intervention_name>
    <description>Vehicle Control will be administered intravenously once daily for 5 consecutive days.</description>
    <arm_group_label>Vehicle Control</arm_group_label>
    <other_name>Intervention 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive RT-PCR assay for SARS CoV-2 in a respiratory tract sample&#xD;
&#xD;
          -  Hospitalized for COVID-19&#xD;
&#xD;
          -  Radiographic diagnosis of pneumonia&#xD;
&#xD;
          -  Respiratory insufficiency&#xD;
&#xD;
          -  Receiving pharmacologic thromboprophylaxis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Premorbid abnormal pulmonary function or disease&#xD;
&#xD;
          -  Concurrent or prior intubation or ventilated support for COVID-19&#xD;
&#xD;
          -  Receiving systemic corticosteroids or other immunomodulators or immunosuppressant&#xD;
             drugs&#xD;
&#xD;
          -  Previous hospitalization for COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alpesh Amin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor &amp; Chair, Department of Medicine University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Tranowski, B.S.</last_name>
    <phone>844-400-6796</phone>
    <email>dtranowski@oryntherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 pneumonia</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19 drug treatment</keyword>
  <keyword>theta-defensins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

